|
|
|
|
LEADER |
03056nmm a2200385 u 4500 |
001 |
EB000665270 |
003 |
EBX01000000000000000518352 |
005 |
00000000000000.0 |
007 |
cr||||||||||||||||||||| |
008 |
140122 ||| eng |
020 |
|
|
|a 9783642569210
|
100 |
1 |
|
|a Abracchio, Maria P.
|e [editor]
|
245 |
0 |
0 |
|a Purinergic and Pyrimidinergic Signalling II
|h Elektronische Ressource
|b Cardiovascular, Respiratory, Immune, Metabolic and Gastrointestinal Tract Function
|c edited by Maria P. Abracchio, Michael Williams
|
250 |
|
|
|a 1st ed. 2001
|
260 |
|
|
|a Berlin, Heidelberg
|b Springer Berlin Heidelberg
|c 2001, 2001
|
300 |
|
|
|a XXVIII, 442 p
|b online resource
|
505 |
0 |
|
|a Section III: Cardiovascular and Renal Systems -- 16 P1 Receptors in the Cardiovascular System -- 17 P1 and P2 Receptors in the Renal System -- 18 P2 Receptors in the Cardiovascular System -- 19 Roles of Purines and Pyrimidines in Endothelium -- 20 P1 and P2 Receptors in Platelets -- 21 Purinergic Signalling in Gut -- 22 P1 Receptors in the Respiratory System -- 23 P2 Receptors in the Respiratory System -- Section IV: Immune System -- 24 Role of P1 Receptors in Inflammation -- 25 Role of P2 Receptors in the Immune System -- 26 On the Role of the P2X7 Receptor in the Immune System -- Section V: Endocrine System -- 27 Purinergic Receptors and the Pharmacology of Type 2 Diabetes -- 28 Purinergic and Pyrimidinergic Receptor Signaling in Bone Cells -- 29 Clinical Opportunities in Purinergic Neuromodulation
|
653 |
|
|
|a Cell Biology
|
653 |
|
|
|a Medicine / Research
|
653 |
|
|
|a Cytology
|
653 |
|
|
|a Biology / Research
|
653 |
|
|
|a Immunology
|
653 |
|
|
|a Human Physiology
|
653 |
|
|
|a Human physiology
|
653 |
|
|
|a Endocrinology
|
653 |
|
|
|a Biomedical Research
|
653 |
|
|
|a Pharmacology
|
700 |
1 |
|
|a Williams, Michael
|e [editor]
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
490 |
0 |
|
|a Handbook of Experimental Pharmacology
|
028 |
5 |
0 |
|a 10.1007/978-3-642-56921-0
|
856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-642-56921-0?nosfx=y
|x Verlag
|3 Volltext
|
082 |
0 |
|
|a 615
|
520 |
|
|
|a Physiological, pharmacological and molecular biological data generated over the past three decades have demonstrated the existence of two major families of extracellular receptors, the P1, a family of four G-protein coupled receptors and the P2, a family of at least 12 receptors responsive to purine (ATP, ADP) and pyrimidine (UTP) nucleotides through which adenosine and ATP can function as extracellular messengers. The present two-part volume represents an integrated compendium of invited chapters by leading researchers in the area focusing on advances in the understanding of purinergic and pyrimidinergic signaling systems, their role(s) in tissue function and pathophysiology and advances in developing potential new medications based on the modulation of P1 and P2 receptor signaling processes. The volumes will thus provide the reader with a topical, comprehensive and integrated overview of this important area
|